ArticleRwanda journal of medicine and health sciences2025
Tumor Necrosis Factor-Alpha (TNF- α) and Antiviral Activities of Artemisia SPP. Extracts on SARS-COV2.
Article in Rwanda journal of medicine and health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The challenges posed by Coronavirus disease 2019 (COVID-19), including treatment resistance, pandemic threats, and vaccine failure, necessitate the need for locally sourced efficacious therapeutic interventions. We investigated the in-vitro antiviral effects of natural medicinal compounds from Artemisia spp., validated by molecular docking, on TNF-α levels in hospitalized SARS-CoV-2 patients from a designated Lagos COVID-19 isolation centre. Methods: Bioactive chemicals in ethanol and dichloromethane (DCM) extracts from freshly collected, dried, and powdered A. afra and A. annua leaves were characterised using UHPLC. A cross-sectional study of 253 hospitalised SARS-CoV-2 patients was conducted to evaluate the extracts' antiviral activity through serum TNF-α modulation; and docking techniques to determine compound-TNF-α binding affinities. Results: Phytochemical screening of A. annua revealed therapeutic constituents ((lactones, monoterpenes, flavonoids, and sesquiterpenes (artemisinin, rutin, and phenolic acids)) confirmed by UHPLC. The dichloromethane extract of A. afra demonstrated greater TNF-α inhibition in critically ill COVID-19 patients unlike ethanol extracts. Molecular docking validated TNF-α binding affinity for most isolated compounds. Conclusions: Artemisia spp. promises antiviral-proinflammatory cytokine regulation, justifying clinical COVID-19 prophylaxis/therapeutic research, especially against resistant SARS-CoV-2 variants. This could reduce vaccination dependency in impoverished nations while addressing vaccine efficacy and local immunity gaps.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.